UY31779A - FORMULATIONS FOR THE EAR TO TREAT OPTICAL DISEASES AND CONDITIONS - Google Patents
FORMULATIONS FOR THE EAR TO TREAT OPTICAL DISEASES AND CONDITIONSInfo
- Publication number
- UY31779A UY31779A UY0001031779A UY31779A UY31779A UY 31779 A UY31779 A UY 31779A UY 0001031779 A UY0001031779 A UY 0001031779A UY 31779 A UY31779 A UY 31779A UY 31779 A UY31779 A UY 31779A
- Authority
- UY
- Uruguay
- Prior art keywords
- ear
- formulations
- conditions
- compositions
- methods
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a composiciones y métodos para el tratamiento de trastornos ópticos con agentes inmunomoduladores y moduladores de la presión del oído. En estos métodos, las composiciones y formulaciones para el oído son administradas localmente a un individuo afligido con un trastorno óptico, a través de la aplicación directa de las composiciones y formulaciones de inmunomoduladores y/o presón del oído sobre las áreas objetivo del oído medio y/o oído interno, o vía perfusión entre el estructuras del oído medio y/o oído interno.The present invention relates to compositions and methods for the treatment of optical disorders with immunomodulatory agents and ear pressure modulators. In these methods, the compositions and formulations for the ear are administered locally to an individual afflicted with an optical disorder, through the direct application of the compositions and formulations of immunomodulators and / or ear pressure on the target areas of the middle ear and / or inner ear, or via perfusion between the structures of the middle ear and / or inner ear.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4654308P | 2008-04-21 | 2008-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31779A true UY31779A (en) | 2009-12-14 |
Family
ID=41665349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001031779A UY31779A (en) | 2008-04-21 | 2009-04-21 | FORMULATIONS FOR THE EAR TO TREAT OPTICAL DISEASES AND CONDITIONS |
Country Status (5)
Country | Link |
---|---|
AR (1) | AR071388A1 (en) |
CL (1) | CL2009000956A1 (en) |
PE (1) | PE20091836A1 (en) |
TW (1) | TWI412370B (en) |
UY (1) | UY31779A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI485145B (en) | 2012-10-26 | 2015-05-21 | Ind Tech Res Inst | P-type organic semiconductor material and optoelectronic device utilizing the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004533A2 (en) * | 1993-08-04 | 1995-02-16 | Andrulis Pharmaceuticals Corporation | Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents |
US6548527B2 (en) * | 2000-03-27 | 2003-04-15 | The General Hospital Corporation | Treatments for immune-mediated ear disorders |
US20070021352A1 (en) * | 2005-07-20 | 2007-01-25 | Cypress Bioscience, Inc. | Prevention and treatment of hearing disorders |
-
2009
- 2009-04-21 AR ARP090101396 patent/AR071388A1/en unknown
- 2009-04-21 PE PE2009000550A patent/PE20091836A1/en not_active Application Discontinuation
- 2009-04-21 UY UY0001031779A patent/UY31779A/en not_active Application Discontinuation
- 2009-04-21 CL CL2009000956A patent/CL2009000956A1/en unknown
- 2009-04-21 TW TW098113275A patent/TWI412370B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW201004633A (en) | 2010-02-01 |
CL2009000956A1 (en) | 2011-02-18 |
TWI412370B (en) | 2013-10-21 |
AR071388A1 (en) | 2010-06-16 |
PE20091836A1 (en) | 2009-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018003142A1 (en) | Integrated stress path modulators | |
BRPI0808775A2 (en) | compounds and compositions as modulators of gpr119 activity | |
MX2020004519A (en) | Modulators of the integrated stress pathway. | |
WO2010011609A3 (en) | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | |
CR11292A (en) | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | |
CR20120625A (en) | METHODS OF TREATMENT AGAINST PANCREATIC CANCER | |
WO2010008995A3 (en) | Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders | |
ECSP12012171A (en) | PHARMACEUTICAL COMPOSITIONS OF THE ESPIRO-OXINDOL COMPOUND FOR TOPICAL ADMINISTRATION AND ITS USES AS THERAPEUTIC AGENTS | |
CL2012001673A1 (en) | Substituted benzamide derivative compounds, as modulators of taar; preparation procedure; pharmaceutical composition; and its use in the treatment of depression, anxiety disorders, bipolar disorder, schizophrenia, epilepsy, migraine, Alzheimer's disease, metabolic disorders, among others. | |
MX2014002668A (en) | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES. | |
PE20151023A1 (en) | TRIAZOLOPYRAZINES | |
CR20140476A (en) | AGENTS TO TREAT DISORDERS INVOLVING THE MODULATION OF RIANODINE RECEPTORS | |
ECSP067019A (en) | COMPOUNDS AND COMPOSITIONS AS RECEPTOR MODULATORS ACTIVATED BY PEROXISOM PROLIFERATOR (PPAR) | |
BR112018001292A2 (en) | methods for better release of active agents to tumors | |
UY32457A (en) | VACCINE OF THE INACTIVATED DENGUE VIRUS | |
WO2010074992A3 (en) | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders | |
EA201690323A1 (en) | METHODS OF TREATING EAR DISEASES IN CHILDREN | |
ECSP11011354A (en) | USEFUL OPTICAL COMPOSITIONS FOR THE TREATMENT OF INTERNAL AND EXTERNAL EAR INFECTIONS IN MAÍFEROS | |
CL2011002766A1 (en) | Carboxamide derived compounds, calpain inhibitors; pharmaceutical composition comprising them; and its use in the treatment of neurodegenerative diseases, alzahimer, pain, among others. | |
CL2012001031A1 (en) | 2-Oxo-1-pyrrolidinyl-imidazothiadiazole derived compounds; pharmaceutical composition comprising them; useful for the treatment of epilepsy, neurological disorders, among others. | |
AR077372A1 (en) | COMPOSITIONS AND METHODS TO TREAT OTHAL OR NASAL OPHTHALM INFECTIONS | |
CL2019002313A1 (en) | Combination of cotinine and antioxidant for resistance to the treatment of depression and correction of the functional deficit of astrocytes induced by depression and other neuropathological conditions. | |
CR11529A (en) | Cycloalkyloxy and heterocycloalkylpyridine compounds as modulators of HISTAMINE H3 RECEPTOR | |
WO2018140792A3 (en) | Neurotrophin mutants for treating hearing loss and other otic disorders | |
EA201991488A1 (en) | POTASSIUM CHANNEL MODULATORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20181025 |